Table 1 Main characteristics and stimulation outcome in patients who provided informed consent for ovarian stimulation and ovarian tissue cryopreservation
Patient | Cancer type | Age | Days of stimulation | Aspirated oocytes (n) | Cryopreserved zygotes after ICSI (n) |
|---|---|---|---|---|---|
1 | Acute myelogenous leukemia | 28 | 9 | 5 | 5 |
2 | Hodgkin’s lymphoma | 25 | 6 | 7 | 4 |
3 | Cervix carcinoma | 31 | 10 | 10 | 5 |
4 | Leiomyosarcoma | 26 | 11 | 13 | 11 |
5 | Breast carcinoma | 35 | 10 | 7 | 5 |
6 | Breast carcinoma | 31 | 8 | 6 | 4 a |
7 | Mesothelioma | 26 | 10 | 10 | 8 |
8 | Hodgkin’s lymphoma | 24 | 8 | 6 | 4 |
9 | Hodgkin’s lymphoma | 30 | 9 a | 25 | 25 b |
10 | Breast carcinoma | 32 | 6 | 7 | 7 b, c |
11 | Breast carcinoma | 30 | 10 | 10 | 5 |
12 | Hodgkin’s lymphoma | 25 | 13 | 4 | 3 |
13 | Non-Hodgkin’s lymphoma | 27 | 11 | 14 | 14 b, c |
14 | Breast carcinoma (hormone receptor–positive) | 33 | 11 | 13 | 7 |